TY  - GEN
AU  - Gitlitz,Barbara J
AU  - Bernstein,Eric
AU  - Santos,Edgardo S
AU  - Otterson,Greg A
AU  - Milne,Ginger
AU  - Syto,Mary
AU  - Burrows,Francis
AU  - Zaknoen,Sara
TI  - A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer
SN  - 1556-1380
PY  - 2015///0120
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Adenocarcinoma, Bronchiolo-Alveolar
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - urine
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Squamous Cell
KW  - Cyclooxygenase 2 Inhibitors
KW  - therapeutic use
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Prospective Studies
KW  - Prostaglandins
KW  - Protein Kinase Inhibitors
KW  - Pyrroles
KW  - Quinazolines
KW  - Sulfonamides
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/JTO.0000000000000082
ER  -